Popul Health MetrPopul Health MetrPopulation Health Metrics1478-7954BioMed Central2401633938487991478-7954-11-1710.1186/1478-7954-11-17ReviewGlobal epidemiology of invasive meningococcal diseaseJafriRabab Z1rubab_rzj@hotmail.comAliAsad1asad.ali@aku.eduMessonnierNancy E2nar5@cdc.govTevi-BenissanCarol3tevibenissanc@who.intDurrheimDavid45david.durrheim@hnehealth.nsw.gov.auEskolaJuhani6juhani.eskola@thl.fiFermonFlorence7florence.fermon@msf.orgKlugmanKeith P89kklugma@emory.eduRamsayMary10mary.ramsay@hpa.org.ukSowSamba1112ssow@medicine.umaryland.eduZhujunShao13shaozhujun@icdc.cnBhuttaZulfiqar A1zulfiqar.bhutta@aku.eduAbramsonJon14jabrams@wakehealth.eduDepartment of Pediatrics and Child Health, Division of Women and Child Health, Aga Khan University, Stadium Road, Karachi, PakistanCenters for Disease Control and Prevention, Atlanta, GA, USAImmunisation, Vaccines and Biologicals, World Health Organisation, Geneva, SwitzerlandSchool of Medicine and Public Health, University of Newcastle, Callaghan, AustraliaHealth Protection, Hunter New England Area, Wallsend, AustraliaFinnish National Institute for Health and Welfare (THL), Helsinki, FinlandInternational vaccination working group, Médécins Sans Frontières, Paris, FranceGlobal Health, Rollins School of Public Health, Emory University, Atlanta, GA, USARespiratory and Meningeal Pathogens Research Unit, University of Witwatersrand and Medical Research Council, Johannesburg, South AfricaImmunisation Department at the Health Protection Agency, Centre for Infections in Colindale, London, UKCenter for Vaccine Development, Ministry of Health, Bamako, MaliSchool of Medicine, University of Maryland, Baltimore, MD, USAInstitute for Communicable Disease Control and Prevention, Beijing, People’s Republic of ChinaWake Forest School of Medicine, Winston-Salem, NC, USA201310920131117172792012692013Copyright © 2013 Jafri et al.; licensee BioMed Central Ltd.2013Jafri et al.; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense strain on the public health system. The worldwide epidemiology of invasive meningococcal disease (IMD) varies markedly by region and over time. This review summarizes the burden of IMD in different countries and identifies the highest-incidence countries where routine preventive programs against Neisseria meningitidis would be most beneficial in providing protection. Available epidemiological data from the past 20 years in World Health Organization and European Centre for Disease Prevention and Control collections and published articles are included in this review, as well as direct communications with leading experts in the field. Countries were grouped into high-, moderate-, and low-incidence countries. The majority of countries in the high-incidence group are found in the African meningitis belt; many moderate-incidence countries are found in the European and African regions, and Australia, while low-incidence countries include many from Europe and the Americas. Priority countries for vaccine intervention are high- and moderate-incidence countries where vaccine-preventable serogroups predominate. Epidemiological data on burden of IMD are needed in countries where this is not known, particularly in South- East Asia and Eastern Mediterranean regions, so evidence-based decisions about the use of meningococcal vaccines can be made.

MeningococcusNeisseria meningitidisInvasive meningococcal diseaseMeningitisEpidemiologyMeningitis belt
Introduction

Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis, pneumonia, and other localized infections. There are 12 serogroups, but the majority of invasive meningococcal infections are caused by organisms from the A, B, C, X, Y, or W-135 serogroups. The annual number of invasive disease cases worldwide is estimated to be at least 1.2 million, with 135,000 deaths related to invasive meningococcal disease (IMD) [1,2]. In countries with high endemicity, the disease burden places an immense strain on the public health system. The risk of long-term disabling sequelae, including cognitive deficit, bilateral hearing loss, motor deficit, seizures, visual impairment, hydrocephalus, and loss of limbs due to tissue necrosis, are highest in low-income countries, where the burden of bacterial meningitis is greatest [3].

To combat IMD, many industrialized countries have included different formulations of meningococcal vaccine in their routine immunization programs. A vaccine against serogroup A has recently been introduced in the African meningitis belt, an area extending from Senegal in the west to Ethiopia in the east [4,5]. However, meningococcal vaccines remain underutilized globally, particularly in resource-limited countries outside the African meningitis belt. To provide cost effective recommendations about the use of meningococcal vaccines, the country-specific burden of IMD must be established [6]. A comprehensive review of IMD incidence, including all countries with at least a basic surveillance infrastructure reporting IMD cases, was conducted. The review provides the most recently published attack rates, predominant serogroups, and at-risk groups from over 80 countries and organizes the data according to priority groups for vaccine intervention.

MethodsSearch strategy and selection criteria

Our sources for the epidemiological data included the National Library of Medicine (PubMed), the World Health Organization (WHO) website of the Weekly Epidemiological Record, and the European Centre for Disease Prevention and Control. We searched PubMed with the following key terms: (“Neisseria meningitidis”) OR (“meningococcal”) OR (“meningococcemia”) OR (“meningococcus”). The search was limited to studies of humans, studies published in English, and dates of publication from January 1, 1990, to December 31, 2010. The initial search yielded 5,336 results from which studies were excluded based on exclusion criteria below. In addition, data were obtained and included from WHO publications in the Weekly Epidemiological Record (WER) for the latest figures from 14 African meningitis belt countries. The European Union Invasive Bacterial Infections Surveillance Network (EU-IBIS), which is maintained by the European Centre for Disease Prevention and Control, was accessed for updated figures for European countries and these data were also included. We searched reference lists in all identified articles for additional articles, and reviewed abstracts and titles and selected studies if it seemed they included aspects of meningococcal epidemiology. From the above literature search we excluded generic worldwide estimates (except to identify original data references), or studies that were limited to immunology, drug resistance, or other non-epidemiological factors.

Organization of data

The WHO definition of a meningococcal disease epidemic (>100 cases/100,000 population/year) applies specifically to the meningitis belt. Other countries rarely experience epidemics with these high attack rates. We classified countries according to the level of endemic meningococcal disease as “high,” “moderate,” and “low” endemicity (Figure 1). This classification is based on country-specific epidemiological data with pre-defined cutoffs of high, moderate, and low endemicity categories and was used by the WHO’s Strategic Advisory Group of Experts on Immunizations (SAGE) in its recently updated recommendations on the use of meningococcal vaccines [7].

A categorization of countries according to IMD attack rates.

ResultsEpidemiology of meningococcal disease at country level

Data on incidence of meningococcal disease are presented below in Tables 1, 2 and 3. Countries are grouped into priority regions according to the definitions above, using national and published data from the last 20 years. Countries not listed in the table have insufficient available IMD epidemiological data to permit accurate classification.

Countries with high endemic rates (>10 cases/100,000 population) and/or > =1 epidemic over the last 20 years

CountryYearIncidence/100,000 populationPredominant serogroupSourceComments
African Region
Angola
1994–2000
19–230
*
[8]
 
Benin
1980–1999
6–57
 
[9,10]
 
Burkina Faso
2004–2009
26–187
 
[11,12]
 
Burundi
1980–1999
158
 
[9]
 
Cameroon
1–224
 
[13]
 
Centrafique
2004–2009
3 3–19.4
 
[12]
 
Chad
9.6–15.9
 
[12]
 
Cote de Ivoire
1980–1999
0-6
 
[14]
Despite its relatively low attack rate, Cote de Ivoire is included in this table due to its location in the meningitis belt
Ethiopia
0–104
A
[9,10]
 
Gambia
4–165
 
[9,15]
 
Ghana
0–108
 
[9,15]
 
Guinea
0–17
 
[12]
 
Guinea Bissau
0–133
 
[9]
 
Kenya
1990
267
 
[16]
 
Mali
2004–2009
2.6–12.9
 
[12]
 
Mauritania
1980–1999
0–14
 
[9]
 
Namibia
4–165
 
[9]
 
Niger
2004–2009
7.8–90.7
 
[17]
 
Nigeria
0.7–52.6
 
[12]
 
RD Congo
7.3–23.7
 
[12]
 
Rwanda
1980–1999
0–28
 
[9]
 
Senegal
0–53
 
 
Incidence >50 in 1983
Tanzania
1980–1999
0–19
 
 
 
Togo
2004–2009
6–13.2
 
[12]
 
Uganda
1980–1999
0–18
 
[14]
 
Eastern Mediterranean Region
Sudan
2008
*
A
[12]
Despite lack of data Sudan is included in this table due to its location in the meningitis belt
Saudi Arabia
2000
 
A, W-135
[18]
225 cases in month after 2000 Hajj season. Data from Saudi Arabia mostly includes cases from the Hajj season.
European Region
No country in this region is in the high rate category
Region of the Americas
Uruguay
2001
30 (pre-vaccine)
B
[19]
Vaccine comprising serogroup C capsular polysaccharide and the outer membrane vesicles of serogroup B meningococcus was used
1.6 (post-vaccine)
South-East Asia Region
No country in this region is in the high rate category
Western Pacific Region
New Zealand
1991–2000
17.4 (pre-vaccine)
B
[20]
An OMV vaccine for Serogroup B was introduced in 2004
2.6 (post-vaccine)
Mongolia1994–199580-90A[21] 

* Data not available.

Countries with moderate endemic rates (2–10 cases/100,000 population per year)

CountryYearIncidence/100,000 populationPredominant serogroupSourceComments
African Region
 
 
 
 
 
South Africa
2000–2005
0.8–4
B in Western Cape
[22]
 
Eastern Mediterranean Region
No country in this region is in the moderate rate category
European Region
Belgium
1999–2010
2.9 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was introduced in 2002
0.89 (post-vaccine)
Denmark
1999–2010
1.19–3.5
B
[23,24]
 
Greece
 
0.49–2.0
C
[23,24]
A conjugate vaccine for group C introduced in 2001 in pediatric population[25]
Ireland
 
14.3 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was
 
 
2.19 (post-vaccine)
 
 
introduced in 2001
Iceland
 
7.6 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was
 
 
0.6 (post-vaccine)
 
 
introduced in 2002
Lithuania
2004–2010
1.4–2.6
*
[23,24]
 
Luxemburg
1999–2010
0.2–5.68
*
[23,24]
 
Malta
1994–2007
0.8–8.9
B, C
[26]
2 peaks in 2000 and 2006
Netherland
1999–2010
3.6 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C was introduced in 2002
0.86 (post-vaccine)
Norway
1992–2010
0.8–4.6
B
[23,27]
 
Portugal
2000–2010
0.74–3.0
B, C
[23,28]
 
Spain
1999–2010
3.52 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C introduced in 2001
0.88 (post vaccine)
Switzerland
1999–2004
1.16–2.36
C
[24]
A conjugate vaccine for group C introduced in 2005
Turkey
1997–2005
0.3–2.2
*
[28]
 
United Kingdom
1999–2010
5.4 (pre-vaccine)
B, C
[23,24]
A conjugate vaccine for group C introduced in 1999
1.63 (post vaccine)
Region of the Americas
Brazil
1998–2006
1–4.5
B, now C
[19]
A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1990
Cuba
1998–2003
3.4-8.5 (pre-vaccine)
B
[29]
A combined vaccine against serogroup B (OMV) and C (polysaccharide) was introduced in 1987
<1 (post-vaccine)
South-East Asia Region
No country in this region is in the moderate rate category
Western Pacific Region
Australia1995–20063.5–7.9 (pre-vaccine)
B[30]A conjugate vaccine for Serogroup C was introduced in 2003
1.4 (post-vaccine)

* Data not available.

Countries with low endemic rates (<2 case/100,000 population per year)

CountryYearIncidence/100,000 populationPredominant serogroupSourceComments
 
 
 
African Region
 
 
 
 
No country in this region is in the low rate category
 
 
 
 
European Region
 
 
Austria
1999–2010
1.02–1.2
B, C
[23,24]
 
Bulgaria
2000–2010
0.11–1.1
*
[23,28]
 
Croatia
1997–2005
0.7–1.3
*
[28]
 
Cyprus
1997–2010
0.13–1.7
*
[23,28]
 
Czech Republic
1999–2010
0.57–1.0
B, C
[23,24]
 
Estonia
2001–2010
0.15–1.6
*
[23,28]
 
Finland
1999–2010
0.64–1.1
B
[23,24]
 
France
0.7–1.13
B, C
 
Germany
0.47–0.73
B, C
 
Hungary
2004–2010
0.3–0.4
*
 
Italy
1999–2010
0.25–0.55
B, C
 
Latvia
2004–2008
0.25–1.03
*
 
Poland
1999–2010
0.17–0.84
B
 
Serbia
2000
0.9
*
[28]
 
Slovakia
2004–2010
0.59–0.9
*
[23,24][23,24]
 
Slovenia
1999–2010
0.3–1.2
*
 
Sweden
2004–2010
0.5–0.7
B, C
 
 
 
 
Eastern Mediterranean Region
 
 
 
 
No country in this region is in the low rate category
 
 
 
 
Region of the Americas
 
 
Argentina
2009
0.6
B
[31]
 
Canada
1985–2006
1.4 (pre-vaccine)
C
[32,33]
Vaccination in 2001–2 in all provinces
0.4 (post-vaccine)
Chile
1998–2006
0.8
B
[19]
 
Columbia
0.3
Y
 
Mexico
0.1
C
 
USA
2000–2009
0.8 (pre-vaccine)
Equal B, C,Y
[34]
Routine vaccination program started in 2005
0.3 (post-vaccine)
Venezuela
 
0.3
Y
[19]
 
 
 
 
South-East Asia Region
 
 
Korea
2002–2008
<0.1
 
[35]
 
Thailand
2007–2008
<0.1
 
[36]
Higher in <5 year olds
 
 
 
Western Pacific Region
 
 
China
2000 onward
<0.2
A, C
[37,38]
 
Japan
1999–2004
<0.02
*
[39]
 
Philippines
2004–2008
<0.1
A
[1]
 
Singapore
2005–2009
0.1–0.2
 
[36,40]
25/100,000 in Hajj pilgrims in 2000 [41]
Taiwan
2000–2001
0.1–0.2
A
[42]
 
 
 
Eastern Mediterranean Region
 
  No country in this region is in the low rate category 

*Data not available.

Significant gaps in data limit description of IMD epidemiology in some parts of the world. In many countries with IMD surveillance, extensive targeted vaccine development and increasing coverage has decreased the burden of disease. In some endemic countries without vaccination, high IMD attack rates continue. The specific regional epidemiology is summarized in Figure 2 and described in terms of WHO regions below.

Distribution of common and predominant meningococcal serogroups by region. Predominant strains are highlighted in bold text.

African region

The African Meningitis Belt, originally characterized by Lapeysonnie in 1963 [5] and modified in 1987, has the highest annual incidence of meningococcal disease in the world with superimposed frequent epidemics that constitute a major public health burden. Outbreaks in the sub-Saharan region coincide with the dry season, which has led to a hypothesis for the potential role of low humidity and seasonal dust-wind blowing from the Sahara (the Harmattan) in damaging the mucosa and producing irritant coughing that aids transmission [34,43].

Twenty-five countries in the African region with an extremely high incidence of meningococcal disease constitute the meningitis belt. To rapidly detect the frequent epidemics, a strong surveillance system exists that monitors the number of cases on an ongoing basis for rapid response. This region has recently benefitted from a major alliance of international health bodies that have developed and are deploying an affordable and effective vaccine against serogroup A meningococcus, which causes the majority of disease in this area, at population level [44].

Serogroup X, previously a rare cause of sporadic meningitis, has been responsible for outbreaks between 2006 and 2010 in Kenya, Niger, Togo, Uganda, and Burkina Faso, the latter with at least 1,300 cases of serogroup X meningitis among the 6,732 reported annual cases [45].

South Africa is included in the moderate-endemicity group, while other countries in this region do not have adequate data to enable derivation of a population-based estimate of their true incidence rates.

Eastern Mediterranean region

Sudan and Saudi Arabia have high endemic rates of serogroup A disease, and have also experienced outbreaks in recent years during the hajj season with serogroup W-135. Other countries in this region do not have adequate data to permit a population-based estimate of true incidence, although outbreaks have been reported among returning travelers from Hajj.

European region

With the exception of a few countries in the eastern part of the European Region, good surveillance data are available from most European countries. Serogroup B and C are responsible for the majority of disease, and implementation of a meningococcal immunization program with adequate vaccine coverage has contributed to decreasing endemic rates so that no country now falls in the high-endemicity group. Fifteen countries from this region are classified as moderate endemicity and 18 as low. Recent epidemiological surveillance indicates an increase of serogroup Y IMD in some parts of Europe, which is now the third most common serogroup after B and C [23].

Region of the Americas

Uruguay remains the only country from this region to have experienced high rates of IMD within the past 20 years. In 2001, it suffered a peak incidence rate of meningococcal disease due to serogroup B and this prompted the introduction of the Cuban outer membrane vesicle (OMV) B vaccine with good coverage and a sharp decline in incidence in subsequent years. Brazil and Cuba have experienced moderate incidence rates, but have also seen significant benefit from the introduction of meningococcal vaccines in their populations [29]. Argentina, Canada, Chile, Columbia, Mexico, the United States, and Venezuela have experienced low levels of IMD in the timeframe defined by this review. Serogroup Y emerged in Colombia and Venezuala, where it became the common disease-causing serogroup in 2006 [19]. The US has a universal meningococcal vaccine (conjugated quadrivalent vaccine given to adolescents) and Canada also recommends a booster dose in this age group following primary immunization at 12 months of age. Other countries in this region do not have adequate data to allow population-based estimates of their true incidence.

South-East Asia Region

Korea and Thailand are the only countries from this region with published population-based estimates, which demonstrate low endemic rates. India has experienced repeated serogroup A epidemics, the most recent in 2005, but data are mostly available only from large city centers [46]. Sporadic and incomplete data from India, Bangladesh, Indonesia, Nepal, and Pakistan preclude their classification, and no data are available from Sri Lanka [36].

Western Pacific

New Zealand and Mongolia have recorded high IMD endemicity. New Zealand experienced an outbreak of serogroup B disease until an aggressive campaign with the OMV vaccine was initiated in 2004 that has contributed in part to lowering the incidence. Mongolia experienced serogroup A epidemics in the early 1990s. Australia currently experiences predominantly serogroup B disease with moderate attack rates after the introduction of a serogroup C vaccine saw a marked decline in rates of disease due to the C serogroup. China, Japan, Korea, Philippines, Singapore, Taiwan, and Thailand all experience low levels of IMD. Other countries in this region do not have adequate population-based data to allow estimation of their true incidence rates.

Age-specific attack rates

In many countries with epidemiological data, particularly in Europe and North America, the age distribution of meningococcal disease demonstrates two peaks [6,47-49]. The highest incidence is in infants less than one year of age, and a secondary rise in incidence occurs in adolescents and young adults. In one study in the meningitis belt, the age-incidence did not plateau until the late 20s. Fifteen years of data from Niger show that children under the age of five were more affected during epidemics when compared to non-epidemic years [50]. However, some studies have suggested a shift toward older age groups during epidemics [51].

The widespread and rapid use of effective antibiotics has contributed to bringing down the case fatality rate of IMD to between 10 and 20 percent, but it is generally higher in developing countries where access to higher levels of care may be delayed [52]. Despite advances in resuscitative techniques, surgical intervention, and critical care, there is a persistent mortality in the early hours of septicemia due to the rapid progression of disease.

Conclusion

IMD is a serious illness that can be rapidly progressive with resulting significant morbidity and mortality, even with treatment. Vaccines are available for the majority of serogroups that cause disease and have proven effective in reducing the disease incidence in countries that have applied them at the population level. Maximizing the global impact of these vaccines requires having them made available in regions that have the highest disease incidence.

This review used available data to define the burden of meningococcal disease in different countries. Countries were classified based on the disease endemicity, and available data on the most prevalent serogroups were reviewed to permit evidence-based decisions on meningococcal vaccine use. These data helped inform SAGE’s new recommendations on the use of meningococcal vaccines. Limitations of the review include exclusion of studies that were not published in English and the absence of an indicator of the quality of surveillance used to derive incidence rates. It is crucial that timely surveillance utilizing new molecular epidemiology tools is implemented to obtain epidemiological data on burden of meningococcal disease in countries where these are not known. With the licensing of a new affordable conjugated vaccine against serogroup A (licensed in Africa) and, more recently, a multicomponent serogroup B vaccine in Europe (January 2013), functioning surveillance will be necessary to monitor the impact of these vaccines through direct immunity and herd protection and allow for optimization of vaccination schedules.

Competing interests

The authors declare that they have no significant competing interests.

Authors’ contributions

All authors have made active contributions in conceptualizing, drafting, and editing this manuscript. All authors read and approved the final manuscript.

Authors’ information

This manuscript describes the major findings of the meningococcal vaccine working group commissioned by the Strategic Advisory Group of Experts (SAGE) of the WHO.

RouphaelNGStephensDSNeisseria meningitidis: biology, microbiology, and epidemiologyMethods Mol Biol201279912021993636Epidemics of meningococcal disease. African meningitis belt, 2001Wkly Epidemiol Rec20017628228811577498EdmondKClarkAKorczakVSSandersonCGriffithsUKRudanIGlobal and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysisLancet Infect Dis20101031732820417414GreenwoodBMWilliams JD, Burnie JThe epidemiology of acute bacterial meningitis in tropical AfricaBacterial meningitis1987London: Academic Press6191LapeyssonnieL[Cerebrospinal Meningitis in Africa]Bull World Health Organ196328 Suppl111414259333HarrisonLHPeltonSIWilder-SmithAHolstJSafadiMAVazquezJATahaMKLaForceFMvon GottbergABorrowRPlotkinSAThe Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal diseaseVaccine2011293363337121376800Meningococcal Vaccines: WHO position paper, November 2011Weekly Epidemiological Record201152154022128384GasparMLeiteFBrumanaLFelixBStellaAAEpidemiology of meningococcal meningitis in Angola, 1994–2000Epidemiol Infect200112742142411811874MolesworthAMThomsonMCConnorSJCresswellMPMorseAPShearsPHartCACuevasLEWhere is the meningitis belt? Defining an area at risk of epidemic meningitis in AfricaTrans R Soc Trop Med Hyg20029624224912174770Epidemics of Meningococcal Disease, African Meningitis Belt, 2001Wkly Epidemiol Rec200176281288RaghunathanPLJonesJDTiendrebeogoSRSanouISangareLKouandaSDabalMLinganiCElieCMJohnsonSPredictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002J Infect Dis200619360761616453255WHOMeningitis season 2007–2008: moderate levels of meningitis activityGlobal Alert and Response-Disease Outbreak News2008Geneva: Wold Health Organisation2001 - Meningococcal disease in the African Meningitis Belt - Update 3Global Alert and Response-Disease Outbreak News2001Geneva: World Health OrganisationMeningococcal disease in the African Meningitis Belt, epidemic season 2006Global Alert and Response-Disease Outbreak News2006World Health OrganisationExpanded Program on Immunization (EPI)Wkly Epidemiol Rec1997721091169127581Epidemic meningococcal disease--Kenya and Tanzania: recommendations for travelers, 1990MMWR Morb Mortal Wkly Rep19903913142104650BoisierPNicolasPDjiboSTahaMKJeanneIMainassaraHBTenebrayBKairoKKGiorginiDChanteauSMeningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in NigerClin Infect Dis20074465766317278055WHOMeningococcal disease in Saudi Arabia and the Netherlands - UpdateGlobal Alert and Response-Disease Outbreak News2000World Health OrganisationSafadiMACintraOAEpidemiology of meningococcal disease in Latin America: current situation and opportunities for preventionNeurol Res20103226327120406604BakerMGMartinDRKieftCELennonDA 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991–2000J Paediatr Child Health200137S13S1911885731MendsaikhanJWattJPMansoorOSuvdmaaNEdmondKLittDJNymadawaPBaopingYAltantsetsegDSlackMChildhood bacterial meningitis in Ulaanbaatar, Mongolia, 2002–2004Clin Infect Dis200948Suppl 2S141S14619191628von GottbergAdu PlessisMCohenCPrenticeESchragSde GouveiaLCoulsonGde JongGKlugmanKEmergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South AfricaClin Infect Dis20084637738618181736Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence dataStockholm: European Centre for Disease Prevention and Control2013TrotterCLChandraMCanoRLarrauriARamsayMEBrehonyCJolleyKAMaidenMCHeubergerSFroschMA surveillance network for meningococcal disease in EuropeFEMS Microbiol Rev200731273617168995KafetzisDAStamboulidisKNTzanakakiGKourea KremastinouJSkevakiCLKonstantopoulosATsoliaMMeningococcal group C disease in Greece during 1993–2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatriciansClin Microbiol Infect20071355055217378929MuscatMSpiteriGCallejaNHaiderJGraySJMelilloJMMamoJCuschieriPInvasive meningococcal disease in Malta: an epidemiological overview, 1994–2007J Med Microbiol2009581492149819589903IversenBGAavitslandPMeningococcal disease in Norway 1992–1995. Epidemiology and fatalityScand J Infect Dis1996282532598863356Meningococcal Disease[http://ec.europa.eu/health/ph_information/dissemination/echi/docs/meningoccocal_en.pdf]DickinsonFOPerezAEBacterial meningitis in children and adolescents: an observational study based on the national surveillance systemBMC Infect Dis2005510316288649Guidelines for the early clinical and public health management of meningococcal disease in Australia. - Revised Edition 20072007Communicable Diseases Network Australia: Commonwealth Department of Health and AgeingEfronAMSorhouetCSalcedoCAbadRRegueiraMVazquezJAW135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in ArgentinaJ Clin Microbiol2009471979198019357205WhalenCMHockinJCRyanAAshtonFThe changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1992. Emergence of a virulent clone of Neisseria meningitidisJAMA19952733903947823384BettingerJAScheifeleDWLe SauxNHalperinSAVaudryWTsangRThe impact of childhood meningococcal serogroup C conjugate vaccine programs in CanadaPediatr Infect Dis J20092822022419209096MacLennanJKafatosGNealKAndrewsNCameronJCRobertsREvansMRCannKBaxterDNMaidenMCStuartJMSocial behavior and meningococcal carriage in British teenagersEmerg Infect Dis20061295095716707051BaeSMKangYHSerological and genetic characterization of meningococcal isolates in KoreaJpn J Infect Dis20086143443719050348VyseAWolterJMChenJNgTSoriano-GabarroMMeningococcal disease in Asia: an under-recognized public health burdenEpidemiol Infect201111921492496HuXSurveillance of epidemiological features for epidemic cerebrospinal meningitis in China during 1980sZhonghua Liu Xing Bing Xue Za Zhi1990113213242125858ShaoZLiWRenJLiangXXuLDiaoBLiMLuMRenHCuiZIdentification of a new Neisseria meningitidis serogroup C clone from Anhui province, ChinaLancet200636741942316458767Infectious Agents Surveillance Report. Meningococcal meningitis, 1999–2004, Japanhttp://idsc.nih.go.jp/iasr/26/300/tpc300.html. (Report IAS ed., vol. 26. pp. 33–34; 2005:33–34Weekly Infectious Disease Bulletin-Ministry of Health, Singaporehttp://www.moh.gov.sg/content/dam/moh_web/Statistics/Infectious_Diseases_Bulletin/2011/December/2011_week_49.pdf. 2011Wilder-SmithAGohKTBarkhamTPatonNIHajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriersClin Infect Dis20033667968312627350WangJLLiuDPYenJJYuCJLiuHCLinCYChangSCClinical features and outcome of sporadic serogroup W135 disease TaiwanBMC Infect Dis20066716420709GreenwoodBMBlakebroughISBradleyAKWaliSWhittleHCMeningococcal disease and season in sub-Saharan AfricaLancet19841133913426145036BishaiDMChampionCSteeleMEThompsonLProduct development partnerships hit their stride: lessons from developing a meningitis vaccine for AfricaHealth Aff (Millwood)2011301058106421653957XieOPollardAJMuellerJENorheimGEmergence of serogroup X meningococcal disease in Africa: need for a vaccineVaccine2013312852286123623866SinclairDPreziosiMPJacob JohnTGreenwoodBThe epidemiology of meningococcal disease in IndiaTrop Med Int Health2010151421143521054695DellEBedfordDMcMahonBNicholsonAMeningococcal disease--management of serogroup C clusters in a hyperendemic areaIr Med J200194166168169Annual report of the Australian Meningococcal Surveillance Programme, 2009Commun Dis Intell201034291302Prevention and control of meningococcal disease: recommendations for use of meningococcal vaccines in pediatric patientsPediatrics200511649650515995007CampagneGSchuchatADjiboSOusseiniACisseLChippauxJPEpidemiology of bacterial meningitis in Niamey, Niger, 1981–96Bull World Health Organ19997749950810427935PeltolaHKatajaJMMakelaPHShift in the age-distribution of meningococcal disease as predictor of an epidemic?Lancet198225955976125738CartwrightKNoahNPeltolaHMeningococcal disease in Europe: epidemiology, mortality, and prevention with conjugate vaccines. Report of a European advisory board meeting Vienna, Austria, 6–8 October, 2000Vaccine2001194347435611534497